uPA、uPAR在前列腺癌组织和血清中的表达及临床意义

目的：探讨前列腺癌患者血清和组织中尿激酶型纤溶酶原激活物（uPA）及其受体（uPAR）的表达与临床意义.方法：应用酶联免疫法（ELISA）和免疫组织化学（SP）方法检测良性前列腺增生（BPH）患者、非骨转移前列腺癌（non-BM PCa）患者及骨转移前列腺癌（BM PCa）患者血清和组织中uPA及uPAR表达.结果：BPH患者、non-BM PCa患者和BM PCa患者血清uPA及uPAR浓度差异有统计学意义（P＜0.01）.non-BM PCa患者血清uPA及uPAR浓度高于BPH患者（P＜0.01）,BM PCa患者高于non-BM PCa患者（P＜0.01）.前列腺癌组织uPA表达阳性率83.34％,uPAR表达阳性率77.78％,良性前列腺增生组织表达阳性率为0,差异有统计学意义（P＜0.01）.结论：uPA、uPA表达与PCa的发生与转移密切相关.

Expression of uPA,uPAR in prostate cancer tissue and serum and its clinical significance

Objective： To investigate the expression of urokinase type plasminogen activator（uPA） and its receptor（uPAR） in serum and tissue of patients with prostate cancer, and its clinical significance. Methods： Using enzyme linked immunosorbent assay（ELISA） and immunohistochemistry （SP） methods to detect expression of uPA and uPAR in serum and tissues of benign prostatic hyperplasia（BPH） patients, non bone metastasis of prostate caneer（non-BM PCa） patients and prostate cancer with bone metastasis（BM PCa） patients. Results： There was statistically different serum uPAR concentration in patients with BPH, noh-BM PCa and BM PCa（P〈0.01）. Non-BM uPA and uPAR in serum of patients with PCa were higher than that of BPH patients（P〈0.01）, BM PCa patients is higher than non-BM PCa patients（P〈0.01）. Prostate cancer tissue uPA expression positive rate was 83.34%, the positive rate of uPAR expression was 77.78%. For benign prostatic hyperplasia tissues, the positive rate was 0, the difference was statistically significant（P〈0.01）. Conclusion： The expression of uPA and uPAR closely related with the occurrence and metastasis of PCa.